Search | Invivogen

#TLR7/8 Ligands

ORN06/LyoVec™ - TLR7/8 Agonist

UUGU ssRNA polymer / LyoVec™ complexed

NF-κB response of HEK-Blue™-derived cells to ORN06/LyoVec™

#TLR7/8 Ligands

Loxoribine - TLR7 Agonist

Guanosine analog - CAS #121288-39-9

NF-κB response of HEK-Blue™-derived cells to loxoribine

#TLR7/8 Ligands

Imiquimod (R837) - TLR7 Agonist

Imidazoquinoline compound - CAS #99011-78-6

NF-κB response of HEK-Blue™-derived cells to imiquimod

NF-κB and IRF responses of HEK-Dual™-derived cells to imiquimod

#TLR7/8 Ligands

Gardiquimod™ - TLR7 Agonist

Imidazoquinoline compound - CAS #1020412-43-4

NF-κB response of HEK-Blue™-derived cells to Gardiquimod™

NF-κB and IRF responses of THP1-Dual™-derived cells to Gardiquimod™

#TLR7/8 Ligands

CL264 - TLR7 Agonist

Adenine analog

NF-κB response of HEK-Blue™-derived cells to CL264

NF-κB and IRF responses of HEK-Dual™-derived cells to CL264

#TLR7/8 Ligands

CL097 - TLR7/TLR8 Agonist

Imidazoquinoline compound - CAS #1026249-18-2

NF-κB response of HEK-Blue™-derived cells to CL097

NF-κB and IRF responses of THP1-Dual™-derived cells to CL097

#TLR7/8 Ligands

CL075 (3M002) - TLR7/TLR8 Agonist

Thiazoquinoline compound - CAS #256922-53-9

NF-κB response of HEK-Blue™-derived cells to CL075

NF-κB and IRF responses of HEK-Dual™-derived cells to CL075

#TLR7/8 Ligands

ssRNA41/LyoVec™ - Negative Control

ssRNA40 negative control / LyoVec™ complexed

NF-κB response of HEK-Blue™ hTLR8 cells to ssRNA41/LyoVec™

#TLR7/8 Ligands

ssRNA40/LyoVec™ - TLR7/8 Agonist

HIV-1-derived ssRNA / LyoVec™ complexed

NF-κB response of HEK-Blue™-derived cells to ssRNA40/LyoVec™

#TLR7/8 Ligands

ssPolyU/LyoVec™ - TLR8 Agonist

RNA homopolymer / LyoVec™ complexed

NF-κB response of HEK-Blue™-derived cells to ssPolyU/LyoVec™

ODN 2216 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class A (Human) | Th1 response

Dose-dependent NF-κB response of ODN 2216 in HEK-Blue™ hTLR9 cells

Dose-dependent NF-κB and IRF responses in THP1-Dual™ hTLR9 cells

ODN 1826 VacciGrade™ - TLR9-based Adjuvant

CpG ODN, Class B (Mouse) | Th1 response

NF-κB response of ODN 1826 in HEK-Blue™-derived cells

NF-κB and IRF responses of ODN 1826 in THP1-Dual™ hTLR9 cells

MPLA-SM VacciGrade™- TLR4-based Adjuvant

Monophosphoryl lipid A | Th1 response

Activation of mouse and human TLR4

Absence of TLR2-activating contaminants

Imiquimod VacciGrade™ (R837) - TLR7-based Adjuvant

Imidazoquinoline compound | Th1 response

NF-κB response of HEK-Blue™-derived cells to imiquimod

NF-κB and IRF responses of HEK-Dual™-derived cells to imiquimod

Flagellin FliC VacciGrade™ - TLR5-based Adjuvant

Recombinant flagellin from S. typhimurium | Th1/Th2 response

Rec FLA-ST dose-dependent activation of TLR5

IFA

Incomplete Freund's adjuvant | Th2 response

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with IFA

Alhydrogel® adjuvant 2%

Aluminium hydroxide gel | Th2 Response

Antibody responses to OVA with different adjuvants

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with Alhydrogel® adjuvant 2%

AddaVax™

Squalene-Oil-in-water | Th1/Th2 response

Anti-Ova mIgG levels at 15, 30 and 45 days after the initial immunization with AddaVax™

MPLA Synthetic VacciGrade™ - TLR4-based Adjuvant

Synthetic monophosphoryl lipid A | Th1 response

MPLAs dose-dependent activation of TLR4

NexaVant™ VacciGrade™ - TLR3 & dsRNA-based Vaccine Adjuvant

Synthetic double stranded RNA | Th1 response

Molecular weight of NexaVant™ (agarose gel)

TLR3 response HEK-Blue™ hTLR3 cells to NexaVant™

IgG level in serum of mice after intramuscular administration

Antigen-specific T cell responses after NexaVant™ treatment